建立基于融合网格的CYP2C18模板系统,并将其应用于药物代谢
Yasushi Yamazoe1, Kouichi Yoshinari2
1Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-Aoba, Aoba-ku, Sendai, 980-8578, Japan; Division of Risk Assessment, National Institute of Health Sciences, Tonomachi 3-25-26, Kawasaki-ku, Kawasaki, 210-9501, Japan.
Drug metabolism and pharmacokinetics
|December 9, 2023
概括
研究人员开发了一个新的系统来预测小酶细胞P450 2C18 (CYP2C18) 如何代谢化学物质. 这有助于推进药物安全性和疗效评估,提供了以前研究不足的CYP酶的数据.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
背景情况:
- 准确估计细胞染色体P450 (CYP) 介导的新陈代谢对于药物的有效性和安全性至关重要.
- 对于小CYP酶 (如CYP2C18) 的代谢数据往往缺乏,这阻碍了全面的化学安全评估.
研究的目的:
- 开发一种新的计算系统来评估由CYP2C18介导的新陈代谢.
- 解决化学安全和药物开发中小CYP酶的数据缺口.
主要方法:
- 使用结构性联体数据重建人类CYP2C18的联体可访问活性位点,以创建基于化的网格的模板.
- 开发一个评估系统,在触发-残留接触时结合连接体运动和结合动态.
- 通过对模拟数据与实验结果的相互比较来验证超过130个CYP2C18配体反应.
主要成果:
- 开发的模板系统准确预测了CYP2C18介导的新陈代谢,与实验数据一致.
- 该研究揭示了CYP2C18的统一相互作用机制,类似于CYP2C8.8.
- 确定了初始触发残留物定位在人类CYP2C酶中独特的催化活动中的作用.
结论:
- 已建立的计算系统提供了一种可靠的方法来评估CYP2C18代谢.
- 这种方法提高了对小CYP酶功能的理解,并有助于改善化学和药物安全性评估.
- 这些发现支持该系统对各种CYP酶的更广泛应用.
相关概念视频
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Drug Metabolism: Phase I Reactions
3.3K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.3K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Hepatic Drug Clearance: Role of Transporters
63
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
63
Phase II Reactions: Glucuronidation
454
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
454
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
41
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
41


